[go: up one dir, main page]

PE20070018A1 - Compuestos heterociclicos como inhibidores de aspartil proteasas - Google Patents

Compuestos heterociclicos como inhibidores de aspartil proteasas

Info

Publication number
PE20070018A1
PE20070018A1 PE2006000661A PE2006000661A PE20070018A1 PE 20070018 A1 PE20070018 A1 PE 20070018A1 PE 2006000661 A PE2006000661 A PE 2006000661A PE 2006000661 A PE2006000661 A PE 2006000661A PE 20070018 A1 PE20070018 A1 PE 20070018A1
Authority
PE
Peru
Prior art keywords
aspartile
proteases
inhibitors
compounds
heterocyclic compounds
Prior art date
Application number
PE2006000661A
Other languages
English (en)
Inventor
Andrew Stamford
Zhaoning Zhu
Brian A Mckittrick
Elizabeth M Smith
Ying Huang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070018A1 publication Critical patent/PE20070018A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REIFERE A COMPUESTOS DE FORMULA (I) DONDE W ES UN ENLACE, -S(O)-, -S(O)2-, -C(=O)-, -O-, ENTRE OTROS; U ES UN ENLACE, -S(O)-, -S(O)2-, -C(O)-, ENTRE OTROS; R ES H, ALQUILO(C1-C20), ARILALQUILO, NO2, ENTRE OTROS; R1 Y R2 SON ALQUILENO, ARILALQUILENO, ENTRE OTROS, O JUNTOS SON UNA CADENA DE (C2-C6) OPCIONALMENTE SUSTITUIDO CON O, C(O), C(S), S(O), ENTRE OTROS; R3 Y R4 SON H, ALQUILO(C1-C20), ARILALQUILO(C6-C14), ARILO(C6-C14), HALO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3'-(4,4-DIFLUORO-8-METIL-2,7-DIOXO-2,4,5,7,8,9-HEXAHIDROIMIDAZO-[2,1-d]-[1,3,5]OXADIAZEPIN-8-IL)-1,1'-BIFENIL-3-CARBONITRILO, 3'-[8-METIL-3-(METILSULFONIL)-2,7-DIOXO-2,4,5,7,8,9-HEXAHIDROIMIDAZO-[1,2-a][1,3,5]TRIAZEPIN-8-IL)-1,1'-BIFENIL-3-CARBONITRILO, 2,2-DIFENIL-1,5,6,7-TETRAHIDROIMIDAZOL[1,2-a]PIRIMIDIN-3-ONA, ENTRE OTROS SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ASPARTIL PROTEASAS SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES TAL COMO HIPERTENSION, INSUFICIENCIA CARDIACA CONGESTIVA, ENFERMEDADES COGNITIVAS Y NEURODEGENERATIVAS TAL COMO ENFERMEDAD DE ALZHEIMER
PE2006000661A 2005-06-14 2006-06-13 Compuestos heterociclicos como inhibidores de aspartil proteasas PE20070018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69032605P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
PE20070018A1 true PE20070018A1 (es) 2007-03-08

Family

ID=37074234

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000661A PE20070018A1 (es) 2005-06-14 2006-06-13 Compuestos heterociclicos como inhibidores de aspartil proteasas

Country Status (17)

Country Link
US (1) US7759354B2 (es)
EP (1) EP1896477B1 (es)
JP (1) JP2008543840A (es)
KR (1) KR20080031189A (es)
CN (1) CN101198609A (es)
AR (1) AR054620A1 (es)
AT (1) ATE482214T1 (es)
AU (1) AU2006259675A1 (es)
CA (1) CA2610812A1 (es)
DE (1) DE602006017073D1 (es)
ES (1) ES2350854T3 (es)
IL (1) IL187623A0 (es)
MX (1) MX2007016175A (es)
PE (1) PE20070018A1 (es)
TW (1) TW200716644A (es)
WO (1) WO2006138192A1 (es)
ZA (1) ZA200710337B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1896478B1 (en) 2005-06-14 2014-05-21 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
AR054620A1 (es) 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
EP2061771A1 (en) * 2006-12-12 2009-05-27 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2689780A1 (en) 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
EP2217604A1 (en) 2007-11-05 2010-08-18 Schering Corporation Gamma secretase modulators
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
EP2305672B1 (en) 2008-06-13 2019-03-27 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
US8450308B2 (en) * 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
CN102282145A (zh) 2008-11-13 2011-12-14 先灵公司 γ分泌酶调节剂
CA2747750A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
ES2571057T3 (es) * 2009-03-13 2016-05-23 Vitae Pharmaceuticals Inc Inhibidores de beta-secretasa
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443119A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
CN102834384A (zh) 2009-12-11 2012-12-19 盐野义制药株式会社 *嗪衍生物
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ベータセクレターゼインヒビター
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
CA2867891C (en) 2012-03-19 2021-09-14 Buck Institute For Research On Aging App specific bace inhibitors (asbis) and uses thereof
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
JP2015532282A (ja) 2012-09-28 2015-11-09 ヴァイティー ファーマシューティカルズ，インコーポレイテッド β−セクレターゼの阻害剤
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
ES2769578T3 (es) 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
JP6321685B2 (ja) 2013-02-25 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
EP3416647A4 (en) 2016-02-18 2019-10-23 Merck Sharp & Dohme Corp. N3-SUBSTITUTED IMINOPYRIMIDINONE AS ANTIMALARIAMIDAL

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
JPS5946518B2 (ja) * 1976-12-23 1984-11-13 第一製薬株式会社 ２，２−又は３，３−ジ置換−イミダゾ〔１，２−ａ〕〔１，３〕ジアザシクロアルカン類
GB8312892D0 (en) * 1983-05-11 1983-06-15 Raychem Ltd Electrical insulator
JPS60173546A (ja) * 1984-02-20 1985-09-06 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像処理方法
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5958920A (en) * 1994-12-02 1999-09-28 The United States Of America As Represented By The Department Of Health And Human Services Aralkyl diazabicycloalkane derivatives for CNS disorders
JP2000514456A (ja) * 1996-07-15 2000-10-31 ブリストル―マイヤーズ・スクイブ・カンパニー ファルネシルプロテイントランスフェラーゼのチアジオキソベンゾジアゼピン阻害剤
FR2756282B1 (fr) * 1996-11-22 1998-12-31 Elf Aquitaine Procede de synthese d'esters de l'acide mercapto-3-propionique
JP2003504301A (ja) * 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
EP1340760A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
CA2457952C (en) * 2001-09-21 2009-11-10 Sanofi-Synthelabo Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h) one derivatives for neurodegenerative disorders
EP1295885A1 (en) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP1340761A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
ATE424383T1 (de) 2003-08-08 2009-03-15 Schering Corp Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren
AR045219A1 (es) 2003-08-08 2005-10-19 Pharmacopeia Inc Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
JP4790624B2 (ja) 2003-11-21 2011-10-12 ジョンズ ホプキンス ユニバーシティ 生体分子パーティションモチーフ及びそれらの使用
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
JPWO2005073365A1 (ja) 2004-01-29 2007-09-13 株式会社 ジャパン・ティッシュ・エンジニアリング 移植用細胞の処理方法、細胞懸濁液、移植用補綴物、および損傷部位の治療方法
DE102004007076A1 (de) * 2004-02-13 2005-08-25 Bayer Cropscience Ag Imidazolopyrimidine
WO2006009655A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
MXPA06014793A (es) * 2004-06-16 2007-02-16 Wyeth Corp Derivados de amino-5, 5-difenilimidazolona para la inhibicion de ??-secretasa.
AR049726A1 (es) 2004-07-22 2006-08-30 Schering Corp Amidas sustituidas inhibidoras de beta secretasa
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
AU2005295814A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease
JP2008516945A (ja) 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
US7534807B2 (en) * 2005-02-18 2009-05-19 North Carolina State University De novo synthesis of bacteriochlorins
EP1896478B1 (en) 2005-06-14 2014-05-21 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
AR053902A1 (es) 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
AR054620A1 (es) 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
EP1896032B1 (en) 2005-06-14 2012-10-31 Merck Sharp & Dohme Corp. The preparation and use of compounds as protease inhibitors
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
CN101193859A (zh) 2005-06-14 2008-06-04 先灵公司 蛋白酶抑制剂的制备和用途
US8110682B2 (en) 2005-06-14 2012-02-07 Schering Corporation Preparation and use of compounds as aspartyl protease inhibitors
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
WO2007050721A2 (en) 2005-10-27 2007-05-03 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2628264A1 (en) 2005-10-31 2007-05-10 Schering Corporation Aspartyl protease inhibitors
BRPI0706623A2 (pt) 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
MX2009005300A (es) 2006-11-17 2009-06-08 Schering Corp Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
EP2061771A1 (en) 2006-12-12 2009-05-27 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system

Also Published As

Publication number Publication date
KR20080031189A (ko) 2008-04-08
CA2610812A1 (en) 2006-12-28
IL187623A0 (en) 2008-03-20
EP1896477A1 (en) 2008-03-12
JP2008543840A (ja) 2008-12-04
US20060281730A1 (en) 2006-12-14
DE602006017073D1 (en) 2010-11-04
US7759354B2 (en) 2010-07-20
CN101198609A (zh) 2008-06-11
TW200716644A (en) 2007-05-01
HK1109151A1 (en) 2008-05-30
MX2007016175A (es) 2008-03-07
ES2350854T3 (es) 2011-01-27
AU2006259675A1 (en) 2006-12-28
WO2006138192A1 (en) 2006-12-28
ATE482214T1 (de) 2010-10-15
EP1896477B1 (en) 2010-09-22
AR054620A1 (es) 2007-07-04
ZA200710337B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
ATE425166T1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
PE20041000A1 (es) Pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
DK1558616T3 (da) Meso-substituerede porphyriner
SE0200979D0 (sv) New compounds
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
UY28922A1 (es) Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación.
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
DE60324155D1 (de) Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen
WO2006042950A3 (fr) Utilisation de derives de pyrrolo- pyraz ines pour le traitement de la mucoviscidose
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR044083A1 (es) Compuestos con actividad anti-inflamatoria
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.

Legal Events

Date Code Title Description
FC Refusal